Monitoring of viral levels during therapy of hepatitis C

Hepatology

Volumn 36, Issue 5 I, 2002, Pages

  Davis, Gary L ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

CLINICAL TRIAL; CONFERENCE PAPER; COST OF ILLNESS; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HUMAN; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERONS; MONITORING, PHYSIOLOGIC; RIBAVIRIN; VIRAL LOAD;

EID: 0036830567     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36798     Document Type: Conference Paper

References (27)

1. Layden JE, Layden TJ. How can mathematics help us understand HCV? Gastroenterology 2001;120:1546-1549.
2. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-231.
3. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon-alpha on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996;23:366-371.
4. Neumann AU, Lam NP, Dehari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy. Science 1998;282:103-107.
5. Neumann AU, Lam NP, Dehari H, Davidian M, Wiley TE, Mika BP, Perelson AS, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000;182:28-35.
6. Bekkering FC, Brouwer JT, Schalm SW, Elewaut A. Hepatitis C viral kinetics. Hepatology 1997;26:1691-1693.
7. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, et al. Viral kinetics in patients with chronic hepatitis treated with standard and peginterferon alfa-2a. Hepatology 2001;120:1438-1447.
8. Herrmann E, Neumann AU, Schmidt JM, Zeuzem S. Hepatitis C virus kinetics. Antiviral Ther 2000;5:85-90.
9. Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001;33:419-423.
10. Layden JE, Layden TJ, Levi-Drummer R, Reddy KR, Paulakos J, Neumann AU. Early viral kinetics of HCV - Predicting treatment response after only 24 hours [Abstract]. Gastroenterology 2001;120:A30.
11. Jessner W, Gschwantler M, Steindl-Numda P, Hofer H, Watkins-Reidel T, Wrba F, Mueller C, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: A pilot study. Lancet 2001;358:1241-1242.
12. Fukutomi T, Nakamuta M, Fukutomi M, Iwao M, Watanabe H, Hiroshige K, Tanabe Y, et al. Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy. J Hepatol 2001;34:100-107.
13. Layden JE, Layden TJ. Viral kinetics of hepatitis C: New insights and remaining limitations. Hepatology 2002;35:967-970.
14. Fried MW, Shiffman ML, Reddy RK, Smith C, Marino G, Gonçales FL Jr, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
15. Manns MP, McHutchison JG, Gordon S, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-965.
16. Davis GL, Balart LA, Schiff ER, Lindsay R, Bodenheimer H, Perillo R, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized controlled trial. N Engl J Med 1989;321:1501-1506.
17. McHutchison JG, Gordon S, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b monotherapy versus interferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C: Results of a U.S. multicenter randomized controlled study. N Engl J Med 1998;339:1485-1492.
18. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000;31:211-218.
19. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131-1137.
20. Pockros PJ, Bain VG, Hunter EB, Conrad A, Balart A, Hollinger FB, Albert D. A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment. J Viral Hepat 1999;6:145-150.
21. Nolte FS, Fried MW, Shiffman ML, Ferreira-Gonzalez A, Garrett CT, Schiff ER, Polyak SJ, et al. Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests. J Clin Microbiol 2001;39:4005-4012.
22. Ferenci P, Shiffman ML, Fried MW, Sulkowski MS, Häussinger D, Zarski JP, Gonçales F, et al. Early prediction of response to 40 KDa peginterferon alfa-2a (Pegasys) plus ribavirin in patients with chronic hepatitis C [Abstract]. Hepatology 2001;34:351A.
23. Hadziyannis SJ, Cheinquer H, Morgan R, Diago M, Jensen DM, Sette H, Ramadori G, et al. PegInterferon alfa-2a (40 KD) (Pegasys) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, double-blind, multicenter study examining effect of duration of treatment and ribavirin dose [Abstract]. J Hepatol 2002;36(Suppl 1):3.
24. Comanor L, Anderson F, Ghany M, Perrillo R, Heathcote EJ, Sherlock C, Zitron I, et al. Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol 2001;96:2968-2972.
25. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 2000;32:818-823.
26. McHutchison J, Davis GL, Esteban-Mur R, Poynard T, Ling MH, Garaud JJ, Albrecht J. Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon alfa-2b alone or in combination with ribavirin [Abstract]. Hepatology 2001;34:244A.
27. Davis GL, Lau JYN, Urdea MS, Neuwald P, Wilber JC, Lindsay K, Perrillo RP, et al. Quantitative detection of hepatitis C virus (HCV) RNA by a solid-phase signal amplification method: Definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994;19:1337-1341.